IVW-1001 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2024
How each study uses IVW-1001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- IVW-1001 Ophthalmic Eyelid Wipe 0.2%
- 2
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
IVIEW Therapeutics Inc. (3)
Studies
Open first, then newest update. How each study uses IVW-1001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase 2b Controlled Study of Dosing Techniques - Part BCompletedPhase 2IVIEW Therapeutics Inc.NCT07161011Written as IVW-1001 Ophthalmic Eyelid Wipe 0.2%
- Phase 2b Controlled StudyCompletedPhase 2IVIEW Therapeutics Inc.NCT07140380Written as IVW-1001 Ophthalmic Eyelid Wipe
- IVW-1001 Phase 1/2 in Subjects With Dry Eye DiseaseCompletedPhase 1/2IVIEW Therapeutics Inc.NCT06400459Written as IVW-1001 Ophthalmic Eyelid Wipe 0.1%